

Analysis of Clinical and Pathological Outcomes of Sentinel Lymph Node Biopsy in the SNAC Trial

Amira Elmadahm
Department of Surgery
School of Medicine
University of Adelaide

A thesis submitted to the University of Adelaide in fulfilment
of the requirements for the degree of Master of Surgery

February 2012

Investigators

Author

Amira Elmadahm

MBBS

Supervisors

Professor P. Grantley Gill

MBBS MD (Adel) FRACS

Head, Breast Endocrine and Surgical Oncology Unit, Royal Adelaide Hospital
Department of Surgery, University Of Adelaide

Dr Melissa Bochner

MBBS, MS, FRACS

Staff Specialist, Breast Endocrine and Surgical Oncology Unit, RAH Clinical
Lecturer, Department of Surgery, University Of Adelaide

Table of Contents

| | |
|---|----|
| Acknowledgment | 1 |
| Copyright Statement | 2 |
| Chapter 1 Abstract | 3 |
| Chapter 2 Aims and objectives | 6 |
| Chapter 3 Introduction and Literature Review | 10 |
| 3.1) Introduction | 11 |
| 3.2) Literature review | 12 |
| 3.2.1) The Concept of sentinel lymph nodes biopsy | 12 |
| 3.2.2) Complete axillary dissection versus sentinel lymph node biopsy | 13 |
| 3.2.3) Accuracy of the sentinel lymph node biopsy | 13 |
| 3.2.4) False Negative Rate (FNR) of sentinel lymph node biopsy | 13 |
| 3.2.5) Lymphatic drainage of the mammary gland | 14 |
| 3.2.6) Clinical factors influencing the sentinel lymph node identification | 16 |
| 3.2.6.a) Age | 16 |
| 3.2.6.b) Body weight | 16 |
| 3.2.6. c) Primary tumour size | 17 |
| 3.2.6.d) Tumour palpability | 18 |
| 3.2.6.e) Site of the primary tumour | 18 |
| 3.2.6. f) Multifocal / multicentric primary breast cancer | 19 |
| 3.2.7) The influence of the primary tumour's histopathological features on the identification of sentinel lymph nodes | 19 |
| 3.2.8) Technical factors affecting the identification of the sentinel lymph node | 20 |
| 3.2.8.1) Surgeon skills | 20 |
| 3.2.8.2) The sentinel lymph nodes mapping substances | 20 |
| 3.2.8.2.1) Blue dye technique | 20 |
| 3.2.8.2.2) Radioactive tracers | 21 |
| 3.2.8.3) The route of injection and the identification of the sentinel lymph node | 22 |
| 3.2.8.4) The optimum number of retrieved sentinel nodes | 23 |
| 3.2.9) Histopathological assessments of sentinel lymph node | 24 |
| 3.2.9.1) Types of histopathological assessments used to examine the sentinel lymph nodes | 24 |
| 3.2.10) Factors predicting the axillary nodes status in breast cancer | 25 |
| 3.2.10.1) Clinical factors | 25 |
| 3.2.10.2) Impact of primary tumour features on the nodal status | 25 |
| 3.2.11) Factors that can predict the status of Non Sentinel Lymph Nodes | 28 |
| 3.2.12) Models predicting the status of non sentinel lymph nodes | 29 |
| 3.2.13) The clinical impact of micrometastases and Isolated Tumour Cells | 30 |
| 3.2.14) The differences between screen detected breast cancers and symptomatic breast cancers | 31 |
| Chapter 4 Methods | 33 |
| 4.1) Randomisation of patients in the SNAC trial | 34 |
| 4.2) Surgical procedures and histopathological assessments | 35 |
| 4.3) Statistical analysis | 36 |
| Chapter 5 Results | 37 |
| 5.1) Sentinel Node Biopsy Versus Axillary Clearance Trial | 38 |
| 5.2) Clinical management of patients in the SANC trial | 39 |

| | |
|--|----|
| 5.2.1) Method of diagnosis and breast surgery | 39 |
| 5.2.2) Time delay of the axillary surgery | 40 |
| 5.2.3) Adjuvant therapy | 40 |
| 5.2.3.a) Chemotherapy | 40 |
| 5.2.3.b) Adjuvant endocrine therapy | 40 |
| 5.2.3.c) Arm morbidity treatment | 41 |
| 5.3) Clinical data of patients in the SNAC trial | 42 |
| 5.3.1) patients' age | 42 |
| 5.3.2) Body Mass Index (BMI) | 43 |
| 5.3.3) Associated co-morbidity | 44 |
| 5.3.4) Primary tumour features | 45 |
| 5.3.5) Techniques used for detecting the sentinel lymph node | 47 |
| 5.3.6) Histopathological features of the primary tumour | 47 |
| 5.4) Overall outcomes of sentinel lymph node identification and the total number of removed sentinel nodes | 48 |
| 5.5) Clinicopathological factors and the overall identification rate of the sentinel lymph node | 50 |
| 5.5.1) Patients' data | 50 |
| 5.5.1.a) The impact of age on the identification rate | 50 |
| 5.5.1. b) The correlation between the BMI and sentinel lymph node detection | 51 |
| 5.5.1.c) The impact of co morbidity on the identification of sentinel lymph node | 51 |
| 5.5.1.d) Correlation between the method of detection of the primary tumour and sentinel lymph node identification | 51 |
| 5.5.2) Primary tumour features influencing the sentinel lymph node identification | 52 |
| 5.5.3) The influence of method of diagnosis and surgical management on the sentinel lymph node identification | 55 |
| 5.5.4) The outcomes of the overall sentinel lymph node detection | 56 |
| 5.5.4.1) Summary of univariate analysis outcomes | 56 |
| 5.5.4.2) The multivariate analysis of overall outcomes of the sentinel lymph node detection | 56 |
| 5.6) Technical factors affecting the sentinel lymph node identification | 57 |
| 5.6.1) Blue dye injection | 57 |
| 5.6.1.1) Outcomes of blue dye injection | 57 |
| 5.6.1.2) The impact of clinicopathological factors on the identification of the blue sentinel lymph node | 59 |
| 5.6.1.3) Summary of univariate and the outcomes of multivariate analysis | 64 |
| 5.6.2) Outcomes of sentinel lymph node biopsy with the blue dye technique only | 65 |
| 5.6.2.1) The impact of clinicopathological factors on the outcomes of blue dye techniques in patients who received blue dye only | 65 |
| 5.6.2.1.1) The impact of clinical data of patients and the primary tumour features on the detection of sentinel lymph nodes using blue dye injection only | 66 |
| 5.6.2.1.2) The influence of histopathological features of primary tumour on the detection of sentinel lymph nodes using the blue dye technique as the sole technique | 69 |
| 5.6.2.1.3) The influence of surgical treatments and the method of detection on the detection of sentinel lymph nodes via sole blue dye | 70 |
| 5.6.2.2) The multivariate analysis of the blue dye technique in patients who received blue dye only | 71 |
| 5.6.3) The detection of sentinel lymph nodes with the preoperative lymphoscintigraphy | 72 |
| 5.6.3.1) Outcomes of preoperative lymphoscintigraphy | 72 |
| 5.6.3.2) Factors influencing the outcomes of preoperative lymphoscintigraphy | 74 |
| 5.6.3.2.1) Clinical Factors and the outcomes of preoperative lymphoscintigraphy | 74 |
| 5.6.3.2.1.a) The clinical factors which influence the visualisation of sentinel lymph node with preoperative lymphoscintigraphy | 74 |

| | | |
|---------------|---|-----|
| 5.6.3.2.1. b) | Clinical features of the primary tumour and the outcomes of preoperative lymphoscintigraphy | 75 |
| 5.6.3.2.2) | The influence of histopathological features of the primary tumour on the visulation of the sentinel lymph nodes | 76 |
| 5.6.3.2.3) | The impact of the method of diagnosis and the surgical management on the visualisation of the sentinel lymph node | 78 |
| 5.6.3.3) | Multivariate analysis outcomes of preoperative lymphoscintigraphy mapping | 79 |
| 5.6.4) | Intraoperative gamma probe detection | 79 |
| 5.6.4.1) | The outcomes of sentinel nodes detected with intraoperative gamma prob | 79 |
| 5.6.4.2) | Factors which influence the detection of hot sentinel lymph nodes | 81 |
| 5.6.4.2.1) | The impact of clinical factors on the identification of sentinel lymph node with the gamma probe | 81 |
| 5.6.4.2.2) | The detection of hot sentinel lymph nodes and the clinical features of the primary tumour | 83 |
| 5.6.4.2.3) | The detection of hot sentinel lymph nodes and the pathological features of the primary tumour | 84 |
| 5.6.4.2.4) | The influence of the method of diagnosis and surgical treatments on the detection of sentinel lymph node by the use of gamma probe | 85 |
| 5.6.4.3) | The univariate analysis outcomes' summary and the multivariate analysis of sentinel lymph nodes detection by the use of the gamma probe | 86 |
| 5.6.4.3.a) | The summary of univariate analysis of factors influencing the detection of hot sentinel nodes | 86 |
| 5.6.4.3. b) | The outcomes of multivariate analysis of factors influencing the detection of the hot sentinel nodes | 87 |
| 5.6.5) | The Combined Technique | 88 |
| 5.6.5.1) | Factors influencing sentinel lymph node detection with the three -technique combination | 88 |
| 5.6.5.1.1) | Clinical factors influencing sentinel lymph node detection via the combined technique | 89 |
| 5.6.5.1.2) | Primary tumour features influencing the sentinel lymph node detection via the combined technique | 91 |
| 5.6.5.1.3) | Histopathological features of the primary tumour and the detection of sentinel lymph node via the combined technique | 92 |
| 5.6.5.1.4) | The surgical management and sentinel lymph node detection with the combined technique | 93 |
| 5.6.5.2) | The outcomes of univariate and multivariate analysis of sentinel lymph nodes detection by the use of the combined technique | 94 |
| 5.6.6) | summary of factor influencing the sentinel lymph node identification with various techniques | 95 |
| 5.6.7) | The variability of identification rate in different centres | 96 |
| 5. 7) | The False Negative Rate (FNR) | 97 |
| 5.8) | The locations of removed sentinel lymph nodes | 100 |
| 5.9) | The potential of different techniques to detect the sentinel lymph nodes in various lymphatic basins | 101 |
| 5.10) | Sentinel lymph nodes located in the internal mammary chain | 102 |
| 5.11) | Pathological outcomes of the sentinel lymph node biopsy in the SNAC trial | 107 |
| 5.11.1) | Details of the involved sentinel lymph nodes in the SNAC trial | 109 |
| 5.12) | The correlation between the clinical and pathological factors and the positivity of the sentinel lymph node | 112 |
| 5.12.1) | The impact of clinicopathological factors on the sentinel lymph nodes involvement | 112 |
| 5.12.2) | The correlation between the total number of positive sentinel nodes and clinicopathological factors | 117 |
| 5.13) | Techniques and Histopathology of sentinel lymph nodes located in the internal mammary chain | 118 |
| 5.14) | The optimal number of the removed sentinel lymph nodes | 121 |
| 5.15) | The techniques which identified the involved sentinel nodes | 122 |
| 5.16) | Non Sentinel Lymph Nodes (NSLNs) status in patients with positive sentinel lymph nodes | 127 |
| 5.17) | Comparison of three nomograms outcomes to predict the positivity of non sentinel lymph nodes | 129 |
| 5.18) | Symptomatic breast cancer versus screen detected breast cancer | 133 |
| 5.18.1) | Clinicopathological features of screen detected breast cancer versus symptomatic breast cancer | 133 |
| 5.18.2) | The lymph node status in screen detected breast cancer versus symptomatic breast cancer | 138 |

Chapter 6 Discussion 140

- 6.1) Postoperative complications of complete axillary dissection versus sentinel lymph node biopsy 141
 - 6.2) Detection of the sentinel lymph nodes 142
 - 6.2.1) Factors which influenced the overall outcomes of sentinel lymph node identification in the SNAC trial 143
 - 6.3) The impact of clinical and pathological factors on the identification of sentinel nodes with different techniques 144
 - 6.3.1) Outcomes of the blue dye technique and factors influencing the identification of blue sentinel nodes 144
 - 6.3.2) Outcomes of preoperative lymphoscintigraphy mapping and factors influencing the identification of blue sentinel nodes 146
 - 6.3.3) Outcomes of the gamma probe detection and factors influencing the identification of hot sentinel nodes 148
 - 6.3.4) Outcomes of the combined technique and factors influencing the identification of sentinel lymph nodes 149
 - 6.4) False Negative Rate (FNR) in the SNAC trial 149
 - 6.5) The location of retrieved sentinel lymph node and the internal mammary sentinel nodes 151
 - 6.6) Histopathological outcomes of the sentinel lymph node biopsy in the SNAC trial 152
 - 6.6.1) Outcomes of pathological assessments of sentinel lymph nodes and identifications of clinical and pathological factors predict the sentinel lymph node status 152
 - 6.6.2) Factors which predict the total number of involved sentinel lymph nodes 155
 - 6.7) Positive internal mammary sentinel lymph nodes 155
 - 6.8) The optimum number of sentinel nodes should be removed by surgeons 156
 - 6.9) Techniques which identified the involved sentinel lymph nodes 158
 - 6.10) Factors which determine the non sentinel lymph node involvement in patients with positive sentinel lymph node 158
 - 6.11) Nomograms predict the status of non sentinel lymph nodes 160
 - 6.12) Outcomes of symptomatic primary tumours versus screen detected primary tumours 162
- References 165
- List of Tables 182
- Table of Figures 187

Abbreviation list

Sentinel Lymph Node Biopsy (SLNB)

Complete Axillary Dissection (CAD)

Sentinel Lymph Node (SLN)

Sentinel Node biopsy versus Axillary Clearance trial (SNAC)

Non Sentinel Lymph Nodes (NSLN)

Internal Mammary Nodes (IMNs)

Preoperative lymphoscintigraphy (LSG)

Acknowledgment

This thesis owes its existence to the help and support of several people. I would like to thank Professor P. Grantley Gill for his enthusiasm, his encouragement and his support particularly during the most difficult period of my life in the last nine months. His guidance helped me during my research and the writing of this thesis. Thanks also go to those who provided me with statistical advice at times of need: Professor Val Gebski, Diana Zannino and Mark Donoghoe.

I would also like to thank my family for the support they provided me throughout my life and in particular, I must acknowledge my mother, without whose love and support, I would not have finished this thesis.

Lastly, I offer my regards and blessings to all those who supported me in any respect during the completion of the project.

Copyright Statement

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution to Amira A.S. Elmadahm and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968. I also give permission for the digital version of my thesis to be made available on the web via the University's digital research repository, the Library catalogue, the Australasian Digital Theses Program (ADTP) and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Amira Elmadahm